Abstract
Background: Colorectal cancer (CRC) is the third most diagnosed cancer globally and the second leading cause of cancer-related deaths. Despite advancements, metastatic CRC (mCRC) has a five-year survival rate below 20%. Next-generation sequencing (NGS) can identify rare actionable mutations and assess tumour mutational burden (TMB), but its clinical utility in mCRC is debated due to limited survival improvement and cost-effectiveness concerns. Methods: This retrospective study included mCRC patients (≥18 years) treated at a single oncology center who underwent NGS during treatment planning. Tumour samples were analyzed using either a 52-gene Oncomine™ Focus Assay or a 500+ gene Oncomine™ Comprehensive Assay Plus. Variants were classified by clinical significance (ESMO ESCAT) and potential benefit (ESMO-MCBS and OncoKBTM). Kaplan-Meier and Cox regression analyses evaluated survival outcomes, with significance at p<0.005. Results: Eighty-six metastatic colorectal cancer (mCRC) patients were analysed, all MMR proficient. Most cases (73.3%) underwent sequencing at metastatic diagnosis, using primary tumour samples (74.4%) and a focused NGS assay (75.6%). A total of 206 somatic variants were detected in 86.0% of patients, 31.1% of which were classified as clinically significant, predominantly KRAS mutations (76.6%), with G12D and G12V variants as the most frequent. Median overall survival (OS) was 39.5 months, with no single mutation predictive of OS. Among 33.7% RAS/BRAF wild-type patients, 65.5% received anti-EGFR therapies. Eleven patients (12.8%) had other actionable variants ESCAT level I-II, including four identified as TMB-high, four KRAS G12C, two BRAF V600E and one HER2 amplification. Four received OncoKbTM level 1-2 and ESMO-MCBS score 4, leading to disease control in three cases. Conclusions: NGS enables the detection of rare variants, supports personalized treatments, and expands therapeutic options. As new drugs emerge and genomic data integration improves, NGS is poised to enhance real-world mCRC management.

This publication has 38 references indexed in Scilit: